ストックスクリーナーアプリを入手
2.41
2.43%
-0.06
前日終値:
$2.47
開ける：
$2.45
24時間の取引高:
25,272
Relative Volume:
0.11
時価総額：
$19.87M
収益：
$2.00M
当期純損益:
$-11.43M
株価収益率:
-1.2315
EPS:
-1.957
ネットキャッシュフロー:
$-10.05M
1週間 パフォーマンス:
+0.84%
1か月 パフォーマンス:
+21.72%
6か月 パフォーマンス:
-69.91%
1年 パフォーマンス:
-27.41%
1日の値動き範囲:
$2.38
$2.45
1週間の範囲:
$2.35
$2.52
52週間の値動き範囲:
$1.81
$12.37
Lipocine Inc Stock (LPCN) Company Profile
名前
Lipocine Inc
セクター
電話
801 994 7383
住所
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.41 | 19.87M | 2.00M | -11.43M | -10.05M | -1.957 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-06-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-11 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 再開されました | H.C. Wainwright | Buy |
| 2016-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
| 2015-06-23 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Lipocine Inc (LPCN) 最新ニュース
Lipocine Inc. (LPCN) Holds Near Support After Modest Gain, Resistance in FocusBull Pennant - dars.gov.et
Form 4 Lipocine Inc For: 30 June By Investing.com - Investing.com Canada
Lipocine (LPCN) CEO Mahesh Patel receives 52,781 stock options grant - Stock Titan
LPCN Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline Progress Remains KeyProfit Inflection Point - dars.gov.et
Enterprise value to revenue forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Price to book forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Price to earnings forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Enterprise value to EBITDA forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Price to sales forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Enterprise value to EBIT forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Lipocine Inc Actuals & Estimates (NASDAQ:LPCN) - TradingView
LPCN Forecast — Price Target — Prediction for 2027 - TradingView
Lipocine Inc (LPCN) Institutional Confidence - TradingKey
Lipocine Inc (LPCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lipocine (LPCN) Holds Steady Near Support Amid Low-Volume TradingOutside Reversal - dars.gov.et
Lipocine (LPCN) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Faces ChallengesProfit Recovery Report - dars.gov.et
Lipocine Inc (LPCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lipocine Inc (LPCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lipocine Inc (LPCN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lipocine Inc (LPCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lipocine Inc (LPCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lipocine Inc (LPCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
LPCN News | LIPOCINE INC (NASDAQ:LPCN) - ChartMill
Lipocine’s Phase 3 Trial Failure Triggers Stock Drop, Strategic Reevaluation - timothysykes.com
LPCN Q1 2026 Earnings: EPS Misses Estimates as No Revenue Reported; Stock Edges Higher - newsline.com
Lipocine (LPCN) holds virtual KOL event on postpartum depression and LPCN 1154 - Stock Titan
LPCN: LPCN 1154 demonstrated rapid, sustained PPD relief with a short, well-tolerated oral regimen - TradingView
LPCN Q1 2026 Earnings: Wider-Than-Anticipated Loss Reflects Continued R&D SpendingGuidance Update - newsline.com
Lipocine Inc. (LPCN) Edges Higher as Stock Consolidates Near SupportKeltner Channel - dars.gov.et
Lipocine Inc. (LPCN) Extends Decline: Key Support Levels in Focus After 7% DropStock Analysis - newsline.com
Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 - Investing.com
Lipocine (NASDAQ: LPCN) holders back directors and expand stock incentive plan - Stock Titan
Lipocine (LPCN) director Higuchi awarded right to buy 1,764 shares at $2.19 - Stock Titan
Lipocine (LPCN) director awarded 1,764 stock options at $2.19 exercise price - Stock Titan
Director Richard Dana Ono awarded 1,764 Lipocine (LPCN) stock options at $2.19 - Stock Titan
Lipocine Plans KOL Webinar on Oral PPD Candidate - TipRanks
Lipocine to Host Virtual KOL Event on LPCN 1154 Phase 3 Data for Postpartum Depression - TradingView
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 - Nasdaq
Lipocine (LPCN) Holds Near $2.25 Support Zone as Market Waits for CatalystsIV Crush Alert - newsline.com
LPCN Q1 2026 Earnings: Wider-Than-Expected Loss as Company Continues to Advance PipelineFinancial Health Score - The Legal Advocate
LPCNLipocine Inc Stock Price and Quote - Finviz
Lipocine Inc. (LPCN) Edges Higher Amid Modest Uptick: Technical Resistance in SightSector Neutral Pair - newsline.com
Lipocine presents Phase 3 LPCN 1154 data for postpartum depression at ASCP - TradingView
[8-K] Lipocine Inc. Reports Material Event - Stock Titan
Lipocine Inc. (LPCN) Edges Higher as Biotech Stock Holds Above Key SupportDividend ETF - The Legal Advocate
Lipocine Inc. (LPCN) Shows Modest Uptick, Trading Near Key Resistance LevelTRIN Signal - The Legal Advocate
Lipocine Inc. (LPCN) Shows Resilience: Breaking Down the $2.26 RallyVolume Rate Change - thelegaladvocate.com
LPCN SEC FilingsLipocine Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lipocine (LPCN) reports Q1 loss, beats revenue estimates - MSN
LPCN: Excluding an outlier site, rapid and durable efficacy with strong safety was demonstrated in PPD - TradingView
Lipocine Inc (LPCN) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):